晚期肝细胞癌-话题@MedSci

#晚期肝细胞癌#

57篇内容 | 1350人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1368209, encodeId=58e71368209a0, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=CSCO 2021：秦叔逵教授报告阿可拉定一线治疗基线较重预后较差晚期肝细胞癌结果, objectType=article, longId=217674, objectId=aa6321e674ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa6321e674ae, replyNumber=0, likeNumber=49, createdTime=2021-09-27, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6321e674ae, moduleTitle=CSCO 2021：秦叔逵教授报告阿可拉定一线治疗基线较重预后较差晚期肝细胞癌结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6321e674ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368208, encodeId=f3b1136820837, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, objectType=article, longId=216786, objectId=af4a216e8623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4a216e8623, replyNumber=0, likeNumber=23, createdTime=2021-09-09, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4a216e8623, moduleTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4a216e8623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368207, encodeId=a9aa136820ecb, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Nat Cancer：新辅助治疗药物卡博替尼和纳武单抗治疗局部晚期肝细胞癌, objectType=article, longId=215171, objectId=df392151e1d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df392151e1d8, replyNumber=0, likeNumber=30, createdTime=2021-08-03, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df392151e1d8, moduleTitle=Nat Cancer：新辅助治疗药物卡博替尼和纳武单抗治疗局部晚期肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df392151e1d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368206, encodeId=c6f7136820678, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, objectType=article, longId=213622, objectId=76842136220f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76842136220f, replyNumber=0, likeNumber=22, createdTime=2021-07-03, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76842136220f, moduleTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76842136220f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368205, encodeId=bcaf13682056f, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=共识解读：免疫联合靶向方案为我国晚期肝细胞癌转化治疗开辟新方向！, objectType=article, longId=212517, objectId=e01721251ecb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e01721251ecb, replyNumber=0, likeNumber=39, createdTime=2021-06-11, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e01721251ecb, moduleTitle=共识解读：免疫联合靶向方案为我国晚期肝细胞癌转化治疗开辟新方向！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e01721251ecb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368204, encodeId=42f0136820410, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=J Gastroenterology H：乐伐替尼能够降低晚期肝细胞癌患者疾病进展风险, objectType=article, longId=212078, objectId=38082120e85d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38082120e85d, replyNumber=0, likeNumber=41, createdTime=2021-06-01, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38082120e85d, moduleTitle=J Gastroenterology H：乐伐替尼能够降低晚期肝细胞癌患者疾病进展风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38082120e85d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368203, encodeId=e3e0136820328, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Br J Cancer：特泊替尼tepotinib与索拉非尼sorafenib对晚期肝细胞癌患者的治疗对比, objectType=article, longId=211713, objectId=6c95211e139d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c95211e139d, replyNumber=0, likeNumber=39, createdTime=2021-05-25, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c95211e139d, moduleTitle=Br J Cancer：特泊替尼tepotinib与索拉非尼sorafenib对晚期肝细胞癌患者的治疗对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c95211e139d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368202, encodeId=c72b136820280, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果, objectType=article, longId=211682, objectId=d50921168225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d50921168225, replyNumber=0, likeNumber=38, createdTime=2021-05-24, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d50921168225, moduleTitle=Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50921168225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368201, encodeId=f68d136820109, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, objectType=article, longId=211561, objectId=4f32211561f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f32211561f9, replyNumber=0, likeNumber=27, createdTime=2021-05-21, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f32211561f9, moduleTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f32211561f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368200, encodeId=a9cb1368200a8, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=“特瑞普利单抗+贝伐珠单抗”一线治疗晚期肝细胞癌临床研究新近进展发布, objectType=article, longId=208886, objectId=8dd6208886d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dd6208886d9, replyNumber=0, likeNumber=42, createdTime=2021-03-25, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dd6208886d9, moduleTitle=“特瑞普利单抗+贝伐珠单抗”一线治疗晚期肝细胞癌临床研究新近进展发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dd6208886d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368199, encodeId=e10e136819935, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Eur Radiol:如何可靠地预测经索拉非尼治疗的晚期肝细胞癌生存率, objectType=article, longId=208195, objectId=2b4e208195f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b4e208195f6, replyNumber=0, likeNumber=40, createdTime=2021-03-10, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b4e208195f6, moduleTitle=Eur Radiol:如何可靠地预测经索拉非尼治疗的晚期肝细胞癌生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b4e208195f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368198, encodeId=70a8136819809, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Br J Cancer：接受雷莫芦单抗治疗的晚期肝细胞癌患者的血清甲胎蛋白水平与临床结局, objectType=article, longId=207029, objectId=892a20e029b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=892a20e029b7, replyNumber=0, likeNumber=38, createdTime=2021-02-11, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=892a20e029b7, moduleTitle=Br J Cancer：接受雷莫芦单抗治疗的晚期肝细胞癌患者的血清甲胎蛋白水平与临床结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=892a20e029b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368197, encodeId=3f07136819e59, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Clin Cancer Res：科济生物靶向GPC3的CAR-T细胞治疗晚期肝细胞癌的1期结果公布，初步取得显著疗效, objectType=article, longId=194140, objectId=8189194140e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8189194140e6, replyNumber=0, likeNumber=24, createdTime=2020-05-15, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8189194140e6, moduleTitle=Clin Cancer Res：科济生物靶向GPC3的CAR-T细胞治疗晚期肝细胞癌的1期结果公布，初步取得显著疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8189194140e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368196, encodeId=7703136819671, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势, objectType=article, longId=186743, objectId=96bb186e4389, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96bb186e4389, replyNumber=0, likeNumber=0, createdTime=2020-01-27, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96bb186e4389, moduleTitle=晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96bb186e4389)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368195, encodeId=d9e11368195e1, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, objectType=article, longId=185534, objectId=9c1618553426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c1618553426, replyNumber=0, likeNumber=24, createdTime=2020-01-03, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c1618553426, moduleTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c1618553426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368194, encodeId=2cc8136819419, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=J Hepatology：普伐他汀与索拉非尼联合治疗并未改善晚期肝细胞癌的生存率, objectType=article, longId=179354, objectId=69551e93547e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69551e93547e, replyNumber=0, likeNumber=21, createdTime=2019-09-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69551e93547e, moduleTitle=J Hepatology：普伐他汀与索拉非尼联合治疗并未改善晚期肝细胞癌的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69551e93547e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368193, encodeId=16871368193f9, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果, objectType=article, longId=167618, objectId=e3fc16e61813, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3fc16e61813, replyNumber=0, likeNumber=27, createdTime=2019-06-05, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3fc16e61813, moduleTitle=2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3fc16e61813)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368192, encodeId=7b16136819219, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处, objectType=article, longId=164528, objectId=3745164528c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3745164528c3, replyNumber=0, likeNumber=26, createdTime=2019-04-20, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3745164528c3, moduleTitle=EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3745164528c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368191, encodeId=d7f41368191c8, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=Lancet Oncol：雷莫芦单抗Ⅲ期REACH-2研究获成功，AFP升高的晚期肝细胞癌患者生存期显著改善, objectType=article, longId=159866, objectId=1aab15986606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1aab15986606, replyNumber=0, likeNumber=37, createdTime=2019-02-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1aab15986606, moduleTitle=Lancet Oncol：雷莫芦单抗Ⅲ期REACH-2研究获成功，AFP升高的晚期肝细胞癌患者生存期显著改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1aab15986606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368190, encodeId=fbba136819017, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, objectTitle=CLIN CANCER RES：SHR-1210联合阿帕替尼治疗晚期肝细胞癌、胃癌或胃食管交界癌, objectType=article, longId=159011, objectId=865615901193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=865615901193, replyNumber=0, likeNumber=34, createdTime=2019-01-28, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=865615901193, moduleTitle=CLIN CANCER RES：SHR-1210联合阿帕替尼治疗晚期肝细胞癌、胃癌或胃食管交界癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=865615901193)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期肝细胞癌

2020-05-29

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

CSCO 2021：秦叔逵教授报告阿可拉定一线治疗基线较重预后较差晚期肝细胞癌结果

2021-09-27

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究

2021-09-09

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Nat Cancer：新辅助治疗药物卡博替尼和纳武单抗治疗局部晚期肝细胞癌

2021-08-03

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新

2021-07-03

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

共识解读：免疫联合靶向方案为我国晚期肝细胞癌转化治疗开辟新方向！

2021-06-11

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

J Gastroenterology H：乐伐替尼能够降低晚期肝细胞癌患者疾病进展风险

2021-06-01

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Br J Cancer：特泊替尼tepotinib与索拉非尼sorafenib对晚期肝细胞癌患者的治疗对比

2021-05-25

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果

2021-05-24

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择

2021-05-21

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

“特瑞普利单抗+贝伐珠单抗”一线治疗晚期肝细胞癌临床研究新近进展发布

2021-03-25

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Eur Radiol:如何可靠地预测经索拉非尼治疗的晚期肝细胞癌生存率

2021-03-10

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Br J Cancer：接受雷莫芦单抗治疗的晚期肝细胞癌患者的血清甲胎蛋白水平与临床结局

2021-02-11

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Clin Cancer Res：科济生物靶向GPC3的CAR-T细胞治疗晚期肝细胞癌的1期结果公布，初步取得显著疗效

2020-05-15

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势

2020-01-27

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功

2020-01-03

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

J Hepatology：普伐他汀与索拉非尼联合治疗并未改善晚期肝细胞癌的生存率

2019-09-14

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果

2019-06-05

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处

2019-04-20

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

Lancet Oncol：雷莫芦单抗Ⅲ期REACH-2研究获成功，AFP升高的晚期肝细胞癌患者生存期显著改善

2019-02-14

hb2008ye (审核中...)

前往app查看评论内容

#晚期肝细胞癌#

CLIN CANCER RES：SHR-1210联合阿帕替尼治疗晚期肝细胞癌、胃癌或胃食管交界癌

2019-01-28

科室
- - 订阅+
  - 更多科室
工具
服务